Table 2.

Summary of patient characteristics

Pt ID	Sex	Age, y	CTCL subtype	Current therapy	Previous therapy
1	M	73	FMF	ECP	None
2	M	84	SS	Brentuximab, vorinostat	PUVA, ECP, vorinostat, MTX, bexarotene, IFNα-2b, romidepsin, gemcitabine/doxorubicin, alemtuzumab
3	M	66	SS	ECP	NB-UVB, topical steroids
4	M	85	SS	ECP	Topical steroids
5	F	71	SS	Gemcitabine	ECP, bexarotene, topical steroids, IFNα-2b, vorinostat, romidepsin, belinostat
6	M	73	SS	Pralatrexate	Romidepsin, ECP, bexarotene, topical steroids
7	F	61	SS	ECP, bexarotene	Topical steroids, phototherapy
8	M	77	SS	Romidepsin, vorinostat	ECP, NB-UVB
9	M	70	SS	Pralatrexate	Romidepsin, vorinostat, mechlorethamine, ECP
10	M	71	MF	ECP, bexarotene	NB-UVB, topical steroids
11	F	79	SS	ECP, bexarotene, vorinostat, INFα-2b	Topical steroids
12	F	64	SS	ECP, bexarotene	Topical steroids
13	F	76	SS	ECP	None
14	M	61	MF	ECP, NB-UVB	None
15	M	67	SS	ECP, bexarotene	None
16	F	40	FMF	ECP, bexarotene	NB-UVB, TSEBT
17	M	66	SS	ECP, bexarotene, NB-UVB, topical steroids	None
18	F	64	MF	ECP, bexarotene, IFNα-2b, IFNγ-1b	None
19	M	87	MF	ECP	MTX, bexarotene, topical steroids
20	M	85	MF	ECP, bexarotene, NB-UVB	Topical steroids
21	M	70	MF (V)	EPOCH	None
22	M	77	MF	ECP, bexarotene	NB-UVB, topical steroids
23	M	52	MF	Gemcitabine	NB-UVB, bexarotene, vorinostat, ECP, IFNα-2b, romidepsin,
24	F	62	MF	ECP, bexarotene, NB-UVB, mechlorethamine	Topical steroids
25	M	62	MF	ECP, bexarotene	Topical steroids

ECP, extracorporeal photopheresis; EPOCH, etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin; F, female; FMF, folliculotropic MF; IFN, interferon; M, male; MF, mycosis fungoides; MTX, methotrexate; NB-UVB, narrow band UV-B; PUVA, psoralen UV light A; SS, Sézary syndrome; TSEBT, total body electron beam therapy; V, visceral involvement.